Ser. No. 08/704,681-7

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, C07K 14/71, C12N 15/86 — A1

(11) International Publication Number: WO 96/30514

(43) International Publication Date: 3 October 1996 (03.10.96)

(21) International Application Number: PCT/US96/01689

(22) International Filing Date: 28 March 1996 (28.03.96)

(30) Priority Data:
08/414,417 31 March 1995 (31.03.95) US

(71) Applicant *(for all designated States except US)*: UNIVERSITY OF WASHINGTON [US/US]; Suite 200, 1107 N.E. 45th Street, Seattle, WA 98105 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CHEEVER, Martin, A. [–/US]; 6825 - 83rd Avenue S.E., Mercer Island, WA 98040 (US). DISIS, Mary, L. [–/US]; 17850 S.E. 192nd Drive, Renton, WA 98055 (US).

(74) Agents: SHARKEY, Richard, G. et al.; Seed and Berry L.L.P., 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: INTRACELLULAR DOMAIN OF THE HER-2/NEU PROTEIN FOR PREVENTION OR TREATMENT OF MALIGNANCIES

(57) Abstract

Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/*neu* protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/*neu* oncogene is associated.

